Tag Archives: CDC

Royal Caribbean, Norwegian Cruise submit health protocols to CDC looking to set sail again

By Nivedita Balu and Helen Coster

(Reuters) – Hoping to set sail again after a long halt due to the COVID-19 pandemic, Royal Caribbean Group and Norwegian Cruise Line Holdings Ltd. said on Monday they submitted a report to the U.S. Centers for Disease Control and Prevention (CDC) detailing health and safety protocols.

The cruise operators detailed 74 steps, including enhanced sanitation practices, controlling shore excursions and better protection for crew members, to protect guests once cruises resume.

Recommendations also include rigorous screening and testing before boarding and plans to address positive infection on board, the companies said.

In an interview with Reuters on Monday, which included the two cruise line chief executives and other members of a panel that developed the guidelines, Norwegian Chief Executive Frank Del Rio said he did not know how much Norwegian would need to pay to implement the panel’s recommendations.

“Put it in context, this is a drop in the bucket,” Del Rio said. “Whatever the number is, and I truly don’t know what it is and I don’t think [Royal Caribbean CEO] Richard [Fain] does either. We are at a zero revenue environment. This is a necessary step to return to service and we’re not really concerned about what the costs are.”

In July, the two companies announced a joint task force to help develop safety standards for restarting their businesses during the coronavirus pandemic.

The cruise industry has taken a major hit from the pandemic, with some of the earliest large clusters of COVID-19 occurring aboard cruise ships.

The CDC first issued a no-sail order on March 14 for all cruise ships and has been extending it since.

Cruise operators have lost about half to two-thirds of their value so far this year. Their shares were last down between 4% and 6% as worries of a second lockdown amid rising coronavirus cases shook broader markets.

(Reporting by Helen Coster in New York and Nivedita Balu in Bengaluru; Editing by Vinay Dwivedi and Dan Grebler)

Explainer: When will COVID-19 vaccines be generally available in the U.S.?

By Carl O’Donnell and Michael Erman

(Reuters) – U.S. President Donald Trump and the head of the Centers for Disease Control and Prevention (CDC) this week disagreed about when a COVID-19 vaccine would become widely available. Trump has said one could initially be available by the Nov. 3 election, while the CDC director said vaccines were likely to reach the general public around mid-2021, an assessment more in line with most experts.

WHAT DOES IT MEAN FOR A VACCINE TO BE GENERALLY AVAILABLE?

General availability is when every American who wants the vaccine can get it. There are currently no COVID-19 vaccines approved by U.S. regulators, although a handful are in late-stage trials to prove they are safe and effective.

Experts estimate that at least 70% of roughly 330 million Americans would need to be immune through a vaccine or prior infection to achieve what is known as herd immunity, which occurs when enough people are immune to prevent the spread of the virus to those unable to get a vaccine.

HOW LONG BEFORE VACCINE PRODUCTION IS FULLY RAMPED UP?

Most vaccines in development will require two doses per person.

The CDC anticipates that 35 million to 45 million doses of vaccines from the first two companies to receive authorization will be available in the United States by the end of this year. The current front runners are Pfizer Inc and Moderna Inc.

Drugmakers have been more ambitious with their calculations. AstraZeneca Plc has said it could deliver as many as 300 million doses of its experimental vaccine in the United States by as early as October. Pfizer and German partner BioNTech SE have said they expect to have 100 million doses available worldwide by the end of 2020, but did not specify how much of that was earmarked for the United States. Moderna on Friday said it is on track to make around 20 million doses by the end of the year and between 500 million and 1 billion doses a year beginning in 2021.

Obtaining enough doses to inoculate everyone in the United States will likely take until later in 2021. CDC Director Robert Redfield told a congressional hearing on Wednesday that vaccines may not be widely available to everyone in the United States until the second or third quarter of next year.

WHO WOULD GET AN APPROVED VACCINE FIRST?

The CDC decision will likely broadly follow recommendations from the National Academies of Sciences, Engineering and Medicine. The CDC has said the earliest inoculations may go to healthcare workers, people at increased risk for severe COVID-19, and essential workers.

It is unclear when a vaccine will be available for children as major drugmakers have yet to include them in late-stage trials. Pfizer and BioNTech have filed with regulators seeking to start recruiting volunteers as young as 16 for vaccine studies.

WHICH COMPANIES WILL LIKELY ROLL OUT A VACCINE QUICKLY?

Pfizer has said it could have compelling evidence that its vaccine works by the end of October. Moderna says it could have similar evidence in November. The vaccines would first need to be approved or authorized for emergency use by U.S. regulators.

Drugmakers have already started manufacturing supplies of their vaccine candidates to be ready as soon as they get the go ahead. The U.S. Department of Defense and the CDC plan to start distribution of vaccines within 24 hours of regulatory authorization.

Several drugmakers including Pfizer, AstraZeneca, Johnson & Johnson and Novavax Inc have all said they expect to produce at least 1 billion doses of their vaccines next year if they get regulatory authorization.

Sanofi SA and GlaxoSmithKline Plc are also working on developing a vaccine they say could be authorized next year.

(Reporting by Carl O’Donnell and Michael Erman in New York; additional reporting by Caroline Humer; editing by Peter Henderson and Bill Berkrot)

What you need to know about the coronavirus right now

(Reuters) – Here’s what you need to know about the coronavirus right now:

Biden rejects Trump claim that vaccine is imminent

U.S. Democratic presidential candidate Joe Biden on Thursday bluntly contradicted President Donald Trump’s suggestion that a coronavirus vaccine may be only weeks away, warning Americans they cannot trust the president’s word.

“The idea that there’s going to be a vaccine and everything’s gonna be fine tomorrow – it’s just not rational,” Biden said during a CNN town hall in Moosic, Pennsylvania.

Trump again said on Wednesday that a vaccine for COVID-19 could be ready for distribution ahead of the Nov. 3 election.

Most health experts, including Robert Redfield, the director of the Centers for Disease Control and Prevention, have said a vaccine will likely not be widely available until mid-2021.

Israel imposes second lockdown

Israel will enter a second nationwide lockdown on Friday at the onset of the Jewish high-holiday season, forcing residents to stay mostly at home amid a resurgence in new coronavirus cases.

The country’s initial lockdown was imposed in late March and eased in May as new cases tapered off, reaching lows in the single digits.

But in the past week, new cases have reached daily highs of over 5,000, and Israeli leaders now acknowledge they lifted measures too soon.

The new lockdown will last three weeks and coincides with the start of the Jewish New Year, Rosh Hashana, traditionally a time for large family gatherings and group prayer.

UK COVID hospital admissions double every eight days

Britain’s health minister said that the novel coronavirus was accelerating across the country, with hospital admissions doubling every eight days, but he refused to say if another national lockdown would be imposed next month.

The United Kingdom has reported the fifth-highest number of deaths from COVID-19 in the world after the United States, Brazil, India and Mexico, according to data collected by Johns Hopkins University of Medicine.

COVID-19 cases started to rise again in Britain in September, with between 3,000 and 4,000 positive tests recorded daily in the last week. More than 10 million people are already in local lockdowns.

China reports highest new cases since Aug. 10

Mainland China reported 32 new COVID-19 cases on Thursday, marking the highest daily increase in more than a month and up sharply from nine cases reported a day earlier.

Although the latest increase still remains well below the peaks seen at the height of the outbreak in China early this year, it is the biggest since Aug. 10 and suggests continued COVID-19 risks stemming from overseas travelers coming into the country as the pandemic rages on in other parts of the world.

The National Health Commission said that all new cases were imported infections. Mainland China has not reported any local COVID-19 infections since mid-August.

Canada’s Ontario clamps down on parties

Canada’s most populous province will clamp down on social gatherings to prevent “reckless careless people” from spreading the coronavirus at illegal parties, Ontario Premier Doug Ford said on Thursday.

His warning came as the nation’s top medical officer said authorities could potentially lose the ability to manage the pandemic.

Indoor social events in Toronto, Canada’s biggest city – along with Ontario’s Peel and Ottawa regions – would be authorized to include no more than 10 people, down from a previous limit of 50, Ford said.

“This is a serious situation, folks. We will throw the book at you if you break the rules,” he told a news conference.

(Compiled by Linda Noakes; Editing by Hugh Lawson)

U.S. CDC reports 196,277 deaths from coronavirus

(Reuters) – The U.S. Centers for Disease Control and Prevention (CDC) on Thursday reported 6,613,331 cases of the new coronavirus, an increase of 41,464 cases from its previous count, and said the number of deaths had risen by 1,224 to 196,277.

The CDC’s tally of cases of the respiratory illness known as COVID-19, caused by the new coronavirus, was as of 4 p.m. ET on Sept. 16 versus its previous report a day earlier.

The CDC figures do not necessarily reflect cases reported by individual states.

(Reporting By Mrinalika Roy in Bengaluru; Editing by Aditya Soni)

U.S. CDC reports 195,053 deaths from coronavirus

(Reuters) – The U.S. Centers for Disease Control and Prevention (CDC) on Wednesday reported 6,571,867 cases of the new coronavirus, an increase of 34,240 cases from its previous count, and said the number of deaths had risen by 961 to 195,053.

The CDC’s tally of cases of the respiratory illness known as COVID-19, caused by a new coronavirus, was of 4 p.m. ET on Sept. 15 versus its previous report a day earlier.

The CDC figures do not necessarily reflect cases reported by individual states.

(Reporting by Dania Nadeem in Bengaluru; Editing by Krishna Chandra Eluri)

U.S. could have capacity of 3 million COVID-19 tests per day, HHS official says

(Reuters) – The United States could have a capacity of 3 million coronavirus tests per day this month, and scale up to a high of as much as 135 million tests a month by October, a top health official told a U.S. Congress panel on Wednesday.

Half of the three million tests would be rapid point-of-care tests, said Admiral Brett Giroir, assistant secretary for health at the U.S. Department of Health and Human Services.

The average turnaround time for lab-based tests was now about 1.5 days on average, Giroir told the U.S. Senate panel.

Officials also stressed that coronavirus vaccines would not be immediately available to the broader public after regulatory clearance.

It would take around 6 to 9 months for enough people to be vaccinated for effective immunization, Centers for Disease Control and Prevention Director Robert Redfield said.

(Reporting by Manas Mishra in Bengaluru and Carl O’ Donnell in New York; Editing by Shinjini Ganguli and Shounak Dasgupta)

U.S. plans to distribute COVID-19 vaccine immediately after regulators authorize it

NEW YORK (Reuters) – The U.S. government on Wednesday said it will start distributing a COVID-19 vaccine within one day of regulatory authorization as it plans for the possibility that a limited number of vaccine doses may be available at the end of the year.

Officials from the Department of Health and Human Services and the Department of Defense on Wednesday held a call with reporters and then released documents on the distribution plans that it is sending to the states and local public health officials.

The federal government will allocate vaccines for each state based on the critical populations recommended first for vaccination by the U.S. Centers for Disease Control and Prevention. That group is expected to include essential healthcare workers.

The document, called the COVID-19 Vaccination Program Interim Playbook, said that “limited COVID-19 vaccine doses may be available by early November 2020 if a COVID-19 vaccine is authorized or licensed by FDA by that time, but COVID-19 vaccine supply may increase substantially in 2021.”

Officials also said they were working to make sure there was no cost to patients for the vaccine.

(Reporting by Michael Erman and Caroline Humer in New York and Mrinalika Roy in Bengaluru; Editing by Chizu Nomiyama; Editing by Chizu Nomiyama)

U.S. COVID-19 death analysis shows greater toll on Black, Hispanic youth: CDC

(Reuters) – A disproportionate percentage of U.S. COVID-19 deaths have been recorded among Black and Hispanic people younger than 21, according to a U.S. study, a reflection of the racial and ethnic make-up of essential workers who have more exposure to COVID-19.

The U.S. Centers for Disease Control and Prevention (CDC) reported that from Feb. 12 through July 31, there were 121 deaths among people younger than the age of 21 in 27 states.

Hispanic, Black, and non-Hispanic American Indian/Alaskan Native people accounted for about 75% of the deaths in that age group, even though they represent 41% of the U.S. population aged under 21.

The researchers looked at data from 47 of 50 states. Among the 121 deaths, 63% were male, 45% were Hispanic and 29% were Black.

Deaths among children younger than one accounted for 10% of the total, 20% of the deaths were among one-to-nine-year olds, while those aged between 10 and 20 years accounted for the rest.

A quarter of the 121 deaths were in previously healthy individuals with no reported underlying medical condition, while 75% had at least one underlying medical condition, including asthma.

The researchers said children from racial and ethnic minority groups, whose parents were likely to be essential workers, could also be over represented because of crowded living conditions, food and housing insecurity, wealth and educational gaps and racial discrimination.

The study appeared in the CDC’s Morbidity and Mortality Weekly Report.

The findings of this study could be limited by incomplete testing and delays in reporting COVID-19-associated deaths, among other things, the researchers said.

(Reporting by Vishwadha Chander in Bengaluru; Editing by Aditya Soni)

U.S. CDC reports 194,092 deaths from coronavirus

(Reuters) – The U.S. Centers for Disease Control and Prevention (CDC) on Tuesday reported 6,537,627 cases of the new coronavirus, an increase of 34,597 cases from its previous count, and said the number of deaths had risen by 387 to 194,092.

The CDC’s tally of cases of the respiratory illness known as COVID-19, caused by a new coronavirus, is as of 4 p.m. ET on Sept. 14 compared with its previous report a day earlier.

The CDC figures do not necessarily reflect cases reported by individual states.

(Reporting By Mrinalika Roy in Bengaluru; Editing by Vinay Dwivedi)

U.S. CDC reports 191,353 deaths from coronavirus

(Reuters) – The U.S. Centers for Disease Control and Prevention (CDC) on Friday reported 6,381,013 cases of the new coronavirus, an increase of 37,451 cases from its previous count, and said that the number of deaths had risen by 1,091 to 191,353.

The CDC reported its tally of cases of the respiratory illness known as COVID-19, caused by a new coronavirus, as of 4 p.m. ET on Sept. 10 versus its previous report a day earlier.

The CDC figures do not necessarily reflect cases reported by individual states.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Maju Samuel)